Focus Issue: Angiotensin-Neprilysin Inhibition: Novel InsightsClinical ResearchNT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
This study was funded by Novartis Pharma AG, Basel, Switzerland. Dr. Pascual-Figal has served on the advisory board for and/or received speaker honoraria from Novartis, Servier, Roche, AstraZeneca, Vifor, Pfizer, and Abbott. Dr. Wachter has served on the advisory board for and/or received speaker honoraria from Boehringer Ingelheim, Bayer, CVRx, Medtronic, Novartis, Pfizer, Sanofi, and Servier; and received research grant supports from Boehringer Ingelheim, the European Union, and Bundesministerium für Bildung und Forschung. Dr. Senni has received consultancy fees and/or speaker honoraria from Novartis, Bayer, Abbott, Merck, AstraZeneca, Vifor Pharma, and Boehringer Ingelheim. Drs. Bao, Noè, Schwende, Butylin, and Prescott are employees of Novartis.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Heart Failure author instructions page.